The Real-world Efficacy of Antiviral therapy in Chronic Hepatitis C (REACH-C) study is a national project which aims to evaluate uptake and outcomes of direct anti-viral therapy for hepatitis C in diverse clinical settings across Australia.
As part of the REACH-C study, ASHM and the Kirby Institute have developed an online form that medical practitioners, who are not experienced in hepatitis C treatment can complete to gain specialist approval to initiate DAA therapy for their patient. The anticipated turn-around time for specialist approval sought via the REACH-C online form is 24 hours.
Once the required data is entered into the online form, it will automatically be sent to a specialist who will review the data and provide the approval to initiate therapy or request further information. The de-identified patient data entered will be collected for the REACH-C Study.
For more information about the online form and specialist approval process, contact Sonja Hill at email@example.com
For more information about the REACH-C study, contact Joanne Carson at firstname.lastname@example.org.
Reach-C online form http://www.reach-c.ashm.org.au/
Information about the study http://www.reach-c.ashm.org.au/about-the-project/
Real world efficacy of antiviral therapy in chronic hepatitis C (REACH-C) in Australia Issue 2, July 2018
Real world efficacy of antiviral therapy in chronic hepatitis C (REACH-C) in Australia Issue 1, July 2017
Privacy | Terms & Conditions | Contact Us | Copyright
Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine | ABN 48 264 545 457 | CFN 17788 | Copyright © 2019. ASHM